interferon-alpha

Overview

Interferon-alpha (IFN-α) is an immunomodulatory cytokine with antiviral and antiproliferative activity. It has been evaluated as adjuvant therapy in HBV-related HCC following resection.

Evidence in the corpus

  • mir26 prognostic/predictive value for benefit from adjuvant IFN-α is derived from HBV-related HCC cohorts and has not been validated in Western HCC where IFN-α is not adjuvant standard of care PMID:24735922
  • Mentioned in comprehensive HCC molecular landscape review as a historical systemic therapy context for hepatocellular carcinoma treatment evolution PMID:24798001
  • Prior aldesleukin/interferon-alpha response data in melanoma used to contextualize the Immune transcriptomic subclass survival advantage identified in TCGA melanoma analysis (n=329); the authors draw parallels with existing immunotherapy data but caution that predictive value for checkpoint blockade is unproven PMID:26091043

Resistance mechanisms

Cancer types (linked)

  • HCC — adjuvant IFN-α in HBV-related resected HCC; mir26 as candidate predictive biomarker

Sources

This page was processed by crosslinker on 2026-05-14. - PMID:24798001

This page was processed by crosslinker on 2026-05-14. - PMID:26091043

This page was processed by crosslinker on 2026-05-14.